Antihemophilic Factor (Recombinant), PEGylated, was approved by the FDA in December 2016 as the product Adynovate [FDA label]. Antihemophilic Factor (Recombinant), PEGylated, is a recombinant full-length human coagulation factor VIII... It has been created to increase the half-life of factor VIII, which decreases dose frequency and decreases the occurrence of bleeding events.
- Mechanism
- Curator reviewed · 3 references
PEG with Factor VIII effectively increases the molecular weight and size of the protein by creating a hydrophilic cloud around the molecule. This molecular change may reduce the susceptibility of this molecule to proteolytic degradation. It is also believed that PEGylation alters the surface charge of the protein that inhibits receptor-mediated clearance. This drug reduces binding to the LRP1 receptor, which normally clears factor VIII from the circulation.
The plasma levels of Factor VIII are increased with replacement therapy, which allows for a temporary correction of the factor deficiency, thus a correction of the bleeding tendency.
- Primary indication
- For the management of hemophilia A (congenital factor VIII deficiency).Curator reviewed · 3 structured indications
- Formula / weight
- 284.0 Da
- First approval
- Canada, 2021
- Also known as
- antihemophilic factor (recombinant), PEGylated-aucl
- Code names
- BAY 94-9027
- Brand names
Resolves to
What you can answer from here — as of June 03, 2022
Which drugs share a target with Antihemophilic factor (recombinant), PEGylated, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account